Excellence in Choice: Polyethylene Glycol Recombinant Human Somatropin Injection For Healthy Growth
Polyethylene Glycol Recombinant Human Somatropin Injection, is a long-acting preparation of growth hormone for the treatment of slow growth in children caused by endogenous growth hormone deficiency, growth disorders in girls due to gonadal hypoplasia (Turner’s Syndrome), and idiopathic short stature (1SS).
Polyethylene Glycol Recombinant Human Somatropin Injection is a long-acting preparation of growth hormone, which is injected subcutaneously once a week.
It has the same effect as human endogenous growth hormone, with the effect of promoting growth regulating bone metabolism; promoting protein synthesis; promoting lipolysis and so on.
Polyethylene Glycol Recombinant Human Somatropin Injection: Advanced Drug Design
Polyethylene Glycol Recombinant Human Somatropin Injection (PEG-rhGH) is a growth hormone produced by recombinant technology, incorporating polyethylene modifier (PEG) modification.
The polymorphic modifier allows for a significant extension of the drug’s half-life in the body, meaning that patients can maintain continuous dosing with fewer injections.
The PEG modification not only improves the stability of the drug, but also effectively reduces immunogenicity and the rate of drug clearance, making PEG-rhGH more effective and safer than traditional recombinant growth hormones during treatment.
When receiving treatment, the frequency of injections will be substantially reduced and the quality of life will be enhanced.
Meeting The Urgent Clinical Need For Growth
Growth hormone deficiency (GHD) is a deficiency of growth death due to abnormal pituitary or hypothalamic function affecting, normal growth growth in children and adults.
In addition to growth retardation in children, lack of growth hormone in adults can also lead to death and mortality problems Although traditional growth cultures have been widely used, patients usually require long-term daily injections and have low treatment compliance.
The launch of Polyethylene Glycol Recombinant Human Growth Hormone Injection provides a solution to this long-standing treatment problem.
Polyethylene Glycol Recombinant Human Somatropin Injection: Hope For Patients
The launch of Polyethylene Glycol Recombinant Human Somatropin Injection offers new hope to the general population of patients with growth hormone deficiency, especially those who are chronically burdened with daily injections.
With this innovative therapy, patients will be able to enjoy a more convenient and efficient treatment experience.
By prolonging the half-life, PEG-rhGH can reduce the number of injections, which will effectively improve treatment adherence and patients’ quality of life.
In conclusion, the launch of polyethylene glycol recombinant human somatropin injection is not only a milestone in the field of growth hormone therapy but also an important breakthrough in biopharmaceutical technology innovation.
However, DengYue‘s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to inquiry us for Polyethylene glycol recombinant human growth hormone.
Information from DengYueMedicine, HongKong Drug Wholesale Distributor, offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
